Aqilion opens Lund office to expedite new initiative for drug projects in early discovery phase

Aqilion recently launched two new innovative drug projects. One of them, Alnitak, is being run with Red Glead Discovery and SARomics Biostructures as prioritized CROs (contract research organizations) and partners in Aqilion’s expansion of new projects in early phase.
Aqilion opens a branch office at Medicon Village in Lund in order to more efficiently work and integrate with its new partners. The office also provides Aqilion with a local presence and expedites collaborative efforts with the university and the infrastructure that Lund offers a life science company.

Aqilion’s Alnitak project has two interesting applications. The goal is to develop drug candidates that bind to a target protein that is essential for both malignant disease development and for inflammatory conditions. A successful project can therefore help to develop new medications to treat orphan drug indications in the field of autoinflammatory diseases, as well as new combination therapies within the field of oncology, primarily intestinal cancer.

Aqilion owns, operates and finances the project and identified, already at the idea stage, Red Glead Discovery and SARomics Biostructures as the CRO companies with the necessary expertise and infrastructure. In addition to a highly experienced team, our new partners offer a technical infrastructure such as a unique platform to identify drug candidates, known as Weak Affinity Chromatography (WAC™), as well as the opportunity to use Max IV in Lund for structure determination over the course of the project. MAX IV is Sweden’s largest and most ambitious research infrastructure initiative and has been the world’s brightest synchrotron light facility since its commissioning in 2016.

“To meet Aqilion’s needs for cutting-edge expertise and experience in drug discovery, we chose Red Glead and SARomics at an early stage. The collaborative effort is driven by a well-integrated and creative process in a common operational structure. I am convinced that this collaborative effort in our new Alnitak drug project will result in synergies, greater knowledge within the team and strong collaboration in the future in brand new projects. I look forward to this opportunity to work with an extremely talented team which, together with us at Aqilion, will create valuable and innovative assets,” says Sarah Fredriksson, CEO of AQILION AB.

“This collaboration with Aqilion and SARomics is extremely exciting. The opportunity to conduct early industrial drug research in Sweden that is not dependent on government grants is really stimulating,” says Johan Evenäs, CEO of Red Glead Discovery AB.

“I look forward to working with Aqilion in this innovative project in which our and Red Glead’s WAC™ technology will be an important component. I have great respect for Aqilion’s bold decision to expand its operations with new projects in early phase,” says Björn Walse, CEO of SARomics Biostructures AB.

For more information, please contact
Sarah Fredriksson, CEO, AQILION AB, +46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About AQILION AB
Aqilion is a Swedish life science company that identifies unique ideas that have the potential to become new medications and refines them into commercially interesting projects. Our projects are based on solid scientific grounds where we can clearly understand the underlying biology, clinical relevance and patient benefit. We focus on indications within inflammation at the interface of oncology and immunology, where we see a great future need, good potential for innovation and a clear interest in the market. Our customers represent the next step in the care chain: the pharmaceutical and biotech industries. Aqilion has its headquarters in Helsingborg, Sweden. Please visit www.aqilion.com.

About Red Glead Discovery AB
Red Glead Discovery is one of Sweden’s fastest growing companies within the Life Science area, focused on preclinical contract research (Drug Discovery) on small molecules and peptides. Since its inception in 2011, the company has served close to 200 customers globally to develop their ideas towards new drugs. The company, founded by seven employees from AstraZeneca R&D Lund, has grown to 33 employees and is located with fit-for-purpose laboratories and offices at Medicon Village in Lund, Sweden. www.redglead.com

About SARomics Biostructures AB
SARomics Biostructures provides premium services within protein crystallization, structure determination, computational chemistry and fragment-based hit generation. SARomics has built a global reputation for its structural biology skills and is currently supporting clients in Asia, Europe, North America and Scandinavia to pursue their drug discovery objectives. www.saromics.com


Aqilion project company Trophea to be liquidated

Today AQILION AB announced that the extraordinary general meeting of the project company Trophea AB, with its wholly owned subsidiary Trophea Development AB, resolved to liquidate the companies. According to the decision, liquidation will begin on December 28, 2019.

The project company Trophea is developing a potential combination product, a topical gel, for the treatment of skin atrophy (thinning of the skin). It is a known problem that the patient may develop skin atrophy as a side effect of prolonged treatment using potent topical steroids (corticosteroids). The extraordinary general meeting of Trophea AB, with its wholly owned subsidiary Trophea Development AB, resolved on December 19, 2019 to liquidate both companies. Liquidation will begin on December 28, 2019.

Aqilion identifies unique life science ideas that have the potential to become new medications and refines them into commercially interesting projects. Each development project is run separately, sometimes as an individual subsidiary, supported by common central resources. As a result of an inventory and validation of the portfolio companies carried out during the year, Aqilion chose not to continue to invest in Trophea. Aqilion’s decision is based on a proactive risk minimization strategy and a sound business approach, in line with the company’s strategy and business model. After a review of all of the project’s scientific and preclinical data combined with a risk and market analysis prior to the previously planned Phase 2 study, the conclusion is that the current study design is not feasible. The project requires a new start, which Aqilion has chosen not to finance.

“Of course, it is a shame not to be able to continue to invest in all projects in Aqilion’s portfolio. However, it is essential for us to stop investing in or to shut down those development projects that do not meet Aqilion’s objectives, and that we do so at an appropriate time. It is equally important to identify risks early in the projects in order to foster proactive leadership and a sound business approach,” says Sarah Fredriksson, CEO of AQILION AB.

The Trophea companies were founded in 2015 by Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB (now known as AQILION AB) along with the network group PULS partners, which was active at the time, and the innovators behind the project idea. Aqilion continued to be the largest owner of Trophea since its inception.

For more information, please contact
Sarah Fredriksson, CEO, AQILION AB, +46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About AQILION AB
Aqilion is a Swedish life science company that identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market. The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner. Aqilion prefersprefers projects aimed at niche markets. Specialty medications (high-cost, high complexity and/or high touch drugs) and orphan drugs (drugs to treat diseases so rare that they would be unprofitable to produce without government assistance) are particularly interesting. Aqilion has its headquarters in Helsingborg. Please visit www.aqilion.com.


Aqilion presents Nomination Committee for the 2020 Annual General Meeting

The Nomination Committee has been appointed and comprises the following members:

  • Helena Arcombe, appointed by the shareholder Länsförsäkringar
  • Malin Ruijsenaars, appointed by the shareholders Grenspecialisten AB and LMK Forward AB
  • Clas Runnberg, appointed to represent other shareholders
  • Lena Mårtensson, appointed to represent Aqilion’s network of advisors 

The members appoint the Chairman between themselves.

The Nomination Committee shall prepare proposals for the 2020 Annual General Meeting regarding the Chairman of the meeting, election of Board members and Chairman of the Board, the fees to be paid to the Board Chairman and the Board members, remuneration to the auditor and election of the auditor.

The Annual General Meeting of AQILION AB will be held on Wednesday, June 10, 2020, at 05.00 p.m. (CET) in Helsingborg, Sweden.

Read more about Aqilion on the company’s website www.aqilion.com.

For more information, please contact
Sarah Fredriksson, CEO, AQILION AB, +46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About AQILION AB
Aqilion is a Swedish life science company that identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market. The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner. Aqilion prefers projects aimed at niche markets. Specialty medications (high-cost, high complexity and/or high touch drugs) and orphan drugs (drugs to treat diseases so rare that they would be unprofitable to produce without government assistance) are particularly interesting. Aqilion has its headquarters in Helsingborg.
Please visit www.aqilion.com.